Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$1.27 - $1.75 $48,008 - $66,153
-37,802 Reduced 60.4%
24,783 $39,000
Q1 2024

Apr 29, 2024

SELL
$1.21 - $1.75 $5,670 - $8,200
-4,686 Reduced 6.97%
62,585 $90,000
Q4 2023

Feb 07, 2024

SELL
$0.89 - $1.41 $6,068 - $9,613
-6,818 Reduced 9.2%
67,271 $90,000
Q3 2023

Nov 02, 2023

BUY
$1.08 - $1.85 $9,464 - $16,211
8,763 Added 13.41%
74,089 $105,000
Q2 2023

Aug 07, 2023

BUY
$0.96 - $1.4 $16,159 - $23,566
16,833 Added 34.71%
65,326 $75,000
Q1 2023

May 09, 2023

SELL
$0.88 - $2.19 $1,168 - $2,908
-1,328 Reduced 2.67%
48,493 $51,000
Q4 2022

Feb 09, 2023

BUY
$1.27 - $2.26 $15,347 - $27,312
12,085 Added 32.03%
49,821 $75,000
Q3 2022

Nov 09, 2022

SELL
$1.41 - $2.79 $1,101 - $2,178
-781 Reduced 2.03%
37,736 $80,000
Q2 2022

Aug 10, 2022

SELL
$1.15 - $2.53 $1,048 - $2,307
-912 Reduced 2.31%
38,517 $52,000
Q1 2022

May 09, 2022

SELL
$1.91 - $3.98 $467 - $975
-245 Reduced 0.62%
39,429 $83,000
Q4 2021

Feb 09, 2022

SELL
$3.53 - $5.5 $68,714 - $107,063
-19,466 Reduced 32.92%
39,674 $147,000
Q3 2021

Nov 09, 2021

SELL
$4.99 - $6.55 $12,834 - $16,846
-2,572 Reduced 4.17%
59,140 $295,000
Q2 2021

Aug 10, 2021

BUY
$6.24 - $8.22 $60,621 - $79,857
9,715 Added 18.68%
61,712 $402,000
Q1 2021

May 10, 2021

BUY
$6.74 - $10.95 $9,294 - $15,100
1,379 Added 2.72%
51,997 $358,000
Q4 2020

Feb 08, 2021

BUY
$3.75 - $10.56 $65,677 - $184,947
17,514 Added 52.91%
50,618 $516,000
Q3 2020

Nov 06, 2020

SELL
$3.5 - $6.2 $41,611 - $73,711
-11,889 Reduced 26.42%
33,104 $115,000
Q2 2020

Sep 04, 2020

BUY
$2.16 - $5.46 $97,184 - $245,661
44,993 New
44,993 $224,000

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $171M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.